Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 17;13(4):843. doi: 10.3390/cancers13040843

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Mitochondrial proteases in multiple myeloma: (A) 20 intrinsic proteases have been described in mitochondria [22,23]. Based on their impact on clinical outcomes in multiple myeloma, this study focuses on LONP1 and OSGEPL1 (asterisks); (B) The transcript levels of the 20 intrinsic mitoproteases in primary multiple myeloma cells were determined based on [24], and the survival of patients with cancer cells expressing each individual mitoprotease either within the top or the bottom quarter was compared in the cohort receiving bortezomib treatment. Only differential expression of LONP1 and OSGEPL1 showed a significant impact on clinical outcomes, with higher expression correlating with a more aggressive cancer and a 1.9- and 1.8-fold shorter median survival, respectively. No difference was observed in the cohort receiving dexamethasone treatment (not shown). The indicated p-values were calculated with the Gehan–Breslow–Wilcoxon test and significance was confirmed with the Mantel–Cox test.